Edition:
India

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

16.43EUR
15 Oct 2019
Change (% chg)

€0.49 (+3.07%)
Prev Close
€15.94
Open
€16.07
Day's High
€16.52
Day's Low
€15.89
Volume
173,600
Avg. Vol
154,694
52-wk High
€18.14
52-wk Low
€12.88

Latest Key Developments (Source: Significant Developments)

Almirall Exercises Its Option With Dermira To License Rights To Lebrikizumab In Europe For Atopic Dermatitis
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Almirall SA ::EXERCISES ITS OPTION WITH DERMIRA TO LICENSE RIGHTS TO LEBRIKIZUMAB IN EUROPE FOR ATOPIC DERMATITIS.ESTIMATES POTENTIAL PEAK SALES OF AROUND 450 MILLION EUROS.WILL PAY DERMIRA AN OPTION EXERCISE FEE OF 50 MILLION DOLLARS.  Full Article

Almirall Q1 EBITDA Up At 80.2 Mln Euros YoY
Monday, 13 May 2019 

May 13 (Reuters) - Almirall SA ::Q1 NET PROFIT 29.9 MILLION EUROS VERSUS 30.9 MILLION EUROS YEAR AGO.Q1 EBITDA 80.2 MILLION EUROS VERSUS 58.0 MILLION EUROS YEAR AGO.Q1 REVENUE 232.2 MILLION EUROS VERSUS 202.0 MILLION EUROS YEAR AGO.CONFIRMS 2019 GUIDANCE, EBITDA AT 290 MILLION EUROS TO 300 MILLION EUROS, REVENUE GROWTH IN LOW DOUBLE DIGITS.  Full Article

Almirall Closes Divestment Of ThermiGen To Celling Biosciences
Monday, 1 Apr 2019 

April 1 (Reuters) - Almirall SA ::DIVESTS THERMIGEN, ITS MEDICAL DEVICE AESTHETICS BUSINESS, COMPLETES ITS STRATEGIC REORIENTATION TOWARDS MEDICAL DERMATOLOGY.THE TRANSACTION DOES NOT AFFECT ALMIRALL GUIDANCE FOR 2019 YEAR.  Full Article

Almirall: FDA Approves Duaklir, New Drug Application For COPD
Monday, 1 Apr 2019 

April 1 (Reuters) - Almirall SA ::FDA APPROVES DUAKLIR, NEW DRUG APPLICATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).APPROVAL AFTER POSITIVE RESULTS OF PHASE III AMPLIFY STUDY WHICH SHOWED SIGNIFICANT IMPROVEMENTS IN LUNG FUNCTION IN PATIENTS WITH MODERATE TO SEVERE COPD.  Full Article

Almirall Secures Up To 120 Mln Euro Loan With EIB To Fund Its R&D
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Almirall SA ::SIGNS LOAN AGREEMENT WITH EUROPEAN INVESTMENT BANK FOR UP TO 120 MILLION EUROS FOR FUNDING OF ITS RESEARCH AND DEVELOPMENT.  Full Article

Almirall Sets Initial Conversion Price Of Bonds Due 2021 At 18.18 Euros/Shr
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Almirall SA ::SAYS INITIAL CONVERSION PRICE OF SENIOR BONDS DUE 2021 HAS BEEN SET AT 18.18 EUROS PER SHARE.SAYS SHARES UNDERLYING BONDS INITIALLY REPRESENT ABOUT 7.91 PERCENT OF CO'S SHARE CAPITAL PRIOR TO THE ISSUE.  Full Article

Almirall To Refinance Bridge Loan Of 400 Million Euros
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Almirall SA ::TO REFINANCE ITS BRIDGE LOAN OF 400 MILLION EUROS.TO ISSUE SENIOR UNSECURED CONVERTIBLE BONDS FOR 250 MLN EUROS AND DUE 2021.TO REFINANCE THE BRIDGE LOAN ALSO WITH SYNDICATED BANK LOAN OF 150 MILLION EUROS.WITH THE REFINANCING DEAL CLOSES FINANCING FOR ITS DERMATOLOGY ACQUISITION IN UNITED STATES.  Full Article

Almirall 9-Month Net Result Turns To Profit Of 93.2 Mln Euros YoY
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Almirall SA ::9-MONTH EBITDA 149.5 MILLION EUROS VERSUS 100.1 MILLION EUROS YEAR AGO.9-MONTH REVENUE 584.0 MILLION EUROS VERSUS 561.6 MILLION EUROS YEAR AGO.9-MONTH RESEARCH AND DEVELOPMENT EXPENSES 57.4 MILLION EUROS VERSUS 67.2 MILLION EUROS YEAR AGO.9-MONTH NET INCOME 93.2 MILLION EUROS VERSUS LOSS 99.7 MILLION EUROS YEAR AGO.9-MONTH NORMALIZED NET PROFIT 78.6 MILLION EUROS VERSUS 22.6 MILLION EUROS YEAR AGO.SAYS IN LINE TO MEET UPDATED GUIDANCE FOR 2018.UPDATES FY 2018 GUIDANCE FOR REVENUE TO MID TO HIGH SINGLE DIGIT GROWTH FROM MID SINGLE-DIGIT GROWTH PREVIOUSLY.SEES 2018 NET SALES LOW DOUBLE-DIGIT GROWTH, 2018 EBITDA AT BETWEEN 205-210 MILLION EUROS.  Full Article

FDA Approves Paratek's Seysara For Treatment Of Moderate To Severe Acne
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Paratek Pharmaceuticals Inc ::FDA APPROVES SEYSARA™ (SARECYCLINE) FOR THE TREATMENT OF MODERATE TO SEVERE ACNE.PARATEK PHARMACEUTICALS INC - PARATEK EARNS $12 MILLION MILESTONE PAYMENT.PARATEK PHARMA - EXCLUSIVELY LICENSED U.S. DEVELOPMENT & COMMERCIALIZATION RIGHTS OF SEYSARA TO ALLERGAN PLC, WHO HAS ASSIGNED SUCH RIGHTS TO ALMIRALL SA.PARATEK PHARMACEUTICALS - RETAINS DEVELOPMENT & COMMERCIALIZATION RIGHTS IN REST OF WORLD.PARATEK PHARMACEUTICALS - NOW ENTITLED TO RECEIVE TIERED ROYALTIES AT RATES RANGING FROM HIGH-SINGLE TO LOW DOUBLE DIGITS ON NET SALES OF SEYSARA.  Full Article

Almirall Receives FDA Approval For Seysara (Sarecycline)
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Almirall SA ::RECEIVES FDA APPROVAL FOR SEYSARA (SARECYCLINE).WILL BE LAUNCHING SEYSARA IN JANUARY 2019 IN US MARKET AND EXPECTS PEAK SALES OF SEYSARA BETWEEN $150 MILLION TO $200 MILLION.SEYSARA TREATS INFLAMMATORY LESIONS OF ACNE IN PATIENTS 9 YEARS OF AGE AND OLDER.NEW PRODUCT COMES FROM ALLERGAN U.S. MEDICAL DERMATOLOGY ACQUISITION AND ITS APPROVAL IS AHEAD OF PLAN.  Full Article

BRIEF-Almirall To Pay Scrip Dividend Of 0.198 Euros Gross/Right

* SAID ON WEDNESDAY IT WOULD INCREASE SHARE CAPITAL BY ISSUING 2.3 MILLION SHARES FOR ITS SCRIP DIVIDEND PROGRAM